New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation
Ahmad Y, Lip GY, Apostolakis S. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation. Expert Review Of Cardiovascular Therapy 2012, 10: 1471-1480. PMID: 23253272, DOI: 10.1586/erc.12.148.Peer-Reviewed Original ResearchConceptsNew oral anticoagulantsParoxysmal atrial fibrillationOral anticoagulantsNonparoxysmal atrial fibrillationAtrial fibrillationHeart failureStroke preventionNew anticoagulantsContemporary phase III trialsAdditional prognostic benefitPhase III trialsPresence of diabetesNew drugsImpact of genderIII trialsPrognostic benefitDiabetes mellitusAnticoagulantsPatientsWarfarinEvent ratesCardiovascular medicineFibrillationMellitusDiabetesStroke Prevention in Atrial Fibrillation: Where are We Now?
Ahmad Y, Lip GY. Stroke Prevention in Atrial Fibrillation: Where are We Now? Clinical Medicine Insights Cardiology 2012, 6: cmc.s8976. PMID: 22408371, PMCID: PMC3296491, DOI: 10.4137/cmc.s8976.Peer-Reviewed Original ResearchStroke preventionAtrial fibrillationOnly successful therapyLow-risk patientsBetter risk stratificationStroke prophylaxisRisk stratificationCommon arrhythmiaNovel anticoagulantsSuccessful therapyWarfarinPatientsGreater mortalityPreventionFibrillationAF researchEffective alternativeNew optionsAnticoagulationImproved management strategiesProphylaxisAnticoagulantsArrhythmiasTherapyMajor progressAnticoagulation in Atrial Fibrillation.
Ahmad Y, Lip GY. Anticoagulation in Atrial Fibrillation. Arrhythmia & Electrophysiology Review 2012, 1: 12-16. PMID: 26835023, PMCID: PMC4711491, DOI: 10.15420/aer.2012.1.12.Peer-Reviewed Original ResearchAtrial fibrillationMost thromboembolic complicationsEfficacy of warfarinNew oral anticoagulantsRisk stratification schemesOral anticoagulationAntithrombotic therapyOral anticoagulantsSevere strokeThromboembolic riskThromboembolic complicationsAF patientsAnticoagulant monitoringCommon arrhythmiaNew anticoagulantsWorse outcomesImproved outcomesNew agentsPatientsAF treatmentStratification schemesAnticoagulationDose variabilityAnticoagulantsWarfarin